Search

The aim of this retrospective study was to compare the cyclosporine C2 blood levels in renal transplant recipients with induction therapy, monitored on C0 levels during the early and long-term post-transplantation periods in different French transplantation centres, to the target values recommended by the International Consensus on Neoral® and used in the Mo2art study. A retrospective study was conducted by the therapeutic drug monitoring (TDM) committee of the French Pharmacological Society. Cyclosporine C0 and C2 concentrations from 168 renal transplant recipients were collected at different post-transplantation periods by six TDM laboratories of transplantation centres from April 2001 to April 2002. Cyclosporine blood levels were determined by fluorescence polarization immunoassay (mFPIA, AxSYM, Abbott) or enzyme immunoassay (EMIT, Dade Behring). Most patients had C0 values in the recommended target ranges, with C2 levels below the targets used in the Mo2art study or proposed by the International Consensus Conference, both during the early and long-term post-transplantation periods. Sixty-eight per cent of patients had C2 below 1500 μg/L ± 20% in the first 2 months post-transplantation and 55% had C2 below 800 μg/L ± 20% in the late post-transplantation period (>1 year). Cyclosporine dose should be increased by 40% on average during the first week post-transplantation period and by 50% during the maintenance period to achieve the C2 targets. In France, most renal transplant recipients receiving induction agents monitored on C0 had C2 levels below the targets recommended by the International Consensus Conference. In clinical practice, the optimal therapeutic windows for CsA monitoring based on C2 needs to be more precisely defined, both during the early and long-term post-transplantation periods in renal transplant recipients receiving induction agents. [ABSTRACT FROM AUTHOR]

The aim of this retrospective study was to compare the cyclosporine C2 blood levels in renal transplant recipients with induction therapy, monitored on C0 levels during the early and long-term post-transplantation periods in different French transplantation centres, to the target values recommended by the International Consensus on Neoral® and used in the Mo2art study. A retrospective study was conducted by the therapeutic drug monitoring (TDM) committee of the French Pharmacological Society. Cyclosporine C0 and C2 concentrations from 168 renal transplant recipients were collected at different post-transplantation periods by six TDM laboratories of transplantation centres from April 2001 to April 2002. Cyclosporine blood levels were determined by fluorescence polarization immunoassay (mFPIA, AxSYM, Abbott) or enzyme immunoassay (EMIT, Dade Behring). Most patients had C0 values in the recommended target ranges, with C2 levels below the targets used in the Mo2art study or proposed by the International Consensus Conference, both during the early and long-term post-transplantation periods. Sixty-eight per cent of patients had C2 below 1500 μg/L ± 20% in the first 2 months post-transplantation and 55% had C2 below 800 μg/L ± 20% in the late post-transplantation period (>1 year). Cyclosporine dose should be increased by 40% on average during the first week post-transplantation period and by 50% during the maintenance period to achieve the C2 targets. In France, most renal transplant recipients receiving induction agents monitored on C0 had C2 levels below the targets recommended by the International Consensus Conference. In clinical practice, the optimal therapeutic windows for CsA monitoring based on C2 needs to be more precisely defined, both during the early and long-term post-transplantation periods in renal transplant recipients receiving induction agents. [ABSTRACT FROM AUTHOR]